INC.L Share News (INC)

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023.

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

IN BRIEF: Incanthera awaits cash flow via skincare deal as loss widens

Incanthera PLC - develops technologies in dermatology and oncology - Pretax loss widens 20% to GBP615,000 in the six months to September 30, from GBP511,000 a year ago. Declares no revenue in either half-year. Looking ahead, the company says: "The post-balance sheet event of the commercial skincare deal is expected to transform Incanthera into a company with significant revenues and profits, generating free cash flow from roll out in Q2 2024." On Monday, Incanthera announced that its Swiss subsidiary Skin & Cell AG signed a deal with Marionnaud, part of the AS Watson Group, to make the skincare brand available exclusively initially in Marionnaud's stores in Switzerland and Austria from the second quarter of next year. Later in 2024, the products will be rolled out in the remaining 1,100 Marionnaud stores across Europe.

IN BRIEF: Incanthera signs skincare stocking deal, raises GBP1 million

Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Incanthera annual loss widens; posts no revenue

Incanthera PLC - Manchester-based oncology and dermatology treatments manufacturer - Sees its pretax loss widen in the year ended March 31 to GBP1.5 million from GBP1.1 million the year before due to an impairment of intellectual property of GBP409,000. Does not declare a dividend "due to the early stage development of the group." Says operating expenses fell to GBP811,000 from GBP937,000 the year before. Chair Tim McCarthy says: "It has been an important, progressive year for Incanthera, in which we have concentrated our expertise on our product offering, evolved existing commercial opportunities and worked hard as a team to progress our core business for the potential ahead of us."

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

(Alliance News) - Incanthera PLC and ImmuPharma PLC on Monday agreed a 12 month extension to their warrant instrument.

Incanthera costs down as it develops commercial pharmaceutical product

(Alliance News) - Incanthera PLC said on Wednesday that operating expenses were down as it remained focussed on developing its current lead pharmaceutical product Sol towards commercialisation.

UK shareholder meetings calendar - next 7 days

Incanthera widens loss as skin cancer asset Sol continues progress

(Alliance News) - Incanthera PLC on Friday reported a widened annual loss in a "very important year" for the company as it continued commercial discussion for its skin cancer asset, Sol.

EARNINGS UPDATES: Incanthera and Botswana Diamonds losses widen

EARNINGS UPDATES: Incanthera and Botswana Diamonds losses widen

IN BRIEF: Incanthera files for Sol skin cancer treatment trademark

IN BRIEF: Incanthera files for Sol skin cancer treatment trademark

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: Renew profit surges; Topps Tiles returns to profit

TRADING UPDATES: Renew profit surges; Topps Tiles returns to profit